Hillevax stock hits 52-week low at $1.52 amid sharp decline

Published 31/03/2025, 14:54
Hillevax stock hits 52-week low at $1.52 amid sharp decline

In a challenging year for Hillevax (HLVX), the biopharmaceutical company’s stock has plummeted to a 52-week low, touching down at $1.52. With a market capitalization of just $78.26 million, the company faces significant headwinds despite maintaining a strong liquidity position with a current ratio of 10.84. This latest price level reflects a stark contrast to the more optimistic valuations the company has seen in the past. Over the past year, Hillevax has experienced a precipitous drop in its stock value, with a staggering 1-year change of -90.71%. Investors have watched with concern as the stock has struggled to regain its footing in a market that has been unforgiving to the biotech sector. The 52-week low serves as a sobering benchmark for Hillevax, marking a period of intense pressure and uncertainty for the company’s financial future. According to InvestingPro analysis, while the company holds more cash than debt, it’s quickly burning through its reserves, with an EBITDA of -$105.08 million. InvestingPro’s Fair Value analysis suggests the stock may be slightly undervalued at current levels, with additional insights available through the subscription service.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.